What was the major commercial milestone announced by 4DMedical (ASX:4DX)?

4DMedical has secured a strategic one-year contract with global pharmaceutical leader GlaxoSmithKline, starting May 1..

How does the GSK contract impact the investment thesis for 4DMedical (ASX:4DX)?

The agreement validates the commercial utility of 4DMedical’s technology within the high-value pharmaceutical R&D sector. By helping GSK improve trial efficiency and patient stratification, 4DMedical demonstrates a scalable B2B revenue stream beyond hospital diagnostic sales.

What new international markets can 4DMedical (ASX:4DX) now access?

4DMedical has received UKCA certification for its CT:VQ™ technology, granting it full clinical access to the United Kingdom’s diagnostic imaging market. This follows a recent CE Mark certification in March 2026, effectively opening the doors to the European and British markets.

What is 4DMedical’s (ASX:4DX) latest regulatory win in North America?

The company has gained regulatory clearance in Canada for its Coronary Artery Calcium (CAC) analysis. This allows 4DMedical to market its heart-health analytics alongside its lung imaging products in the Canadian healthcare system.

Why is 4DMedical’s (ASX:4DX) inclusion in the S&P/ASX 200 significant for retail traders?

Effective 20 April 2026, 4DMedical has been added to the S&P/ASX 200 Index. For investors, this move typically triggers mandatory buying from index-tracking ETFs and institutional funds, which can increase trading liquidity and market visibility.

What are the key bull and bear points for 4DMedical (ASX:4DX) after this news?

The bull case focuses on rapid regulatory expansion (UK, Canada, Europe) and the validation provided by the GSK contract. The bear case involves the commercially confidential nature of the GSK contract value, which makes it difficult to model exact revenue impact in the short term.

How does the new US reimbursement pathway affect 4DMedical (ASX:4DX)?

The CMS has established a new US reimbursement pathway for AI-based opportunistic coronary calcium analysis from routine chest CT scans.

What should investors watch for in the next 4DMedical (ASX:4DX) update?

Investors should look for updates regarding the "materiality" of new contracts and evidence of revenue growth in the UK and Canadian markets.

4DMedical signs GSK deal and joins ASX 200

Written by Mahathir BayenaPublished Apr. 20 2026Last Updated Apr. 20 2026

4DMedical (ASX:4DX) announced a leap in its global commercial strategy, headlined by a new strategic contract with pharmaceutical giant GlaxoSmithKline.

Under the one-year agreement commencing May 1, 4DMedical will provide its proprietary lung imaging analytics to support GSK’s pulmonary drug development and clinical research.

By delivering sensitive, quantitative biomarkers, the technology aims to enhance trial efficiency and improve longitudinal disease assessment, further cementing the company’s role as a preferred provider for the world’s leading biopharmaceutical firms.

The announcement coincides with a breakthrough in regulatory expansion, as 4DMedical’s CT:VQ technology received UKCA certification.

The clearance grants clinical access to the United Kingdom’s diagnostic imaging market, where millions of chest CT scans are performed annually.

This follows recent CE Mark certification, significantly broadening the company's European footprint.

Furthermore, 4DMedical has gained Canadian clearance for its coronary artery calcium analysis, timed with its participation at the Canadian Association of Radiologists annual scientific meeting.

At the time of reporting, 4DMedical’s share price was $5.88.